Soluble C5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome

American Journal of Kidney Diseases

Volumn 65, Issue 6, 2015, Pages 968-969

  Bu, Fengxiao ^a   Zhang, Yuzhou ^a   Thomas, Christie ^a   Smith, Richard J H ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATININE; LACTATE DEHYDROGENASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

COMPLEMENT ACTIVATION; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; LETTER; REMISSION; ADOLESCENT; CASE CONTROL STUDY; COHORT ANALYSIS; FEMALE; MALE; METABOLISM; PREDICTIVE VALUE; THROMBOCYTOPENIA; YOUNG ADULT;

ADOLESCENT; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; COMPLEMENT ACTIVATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 84930472724     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.02.326     Document Type: Letter

References (4)

1. C.M. Legendre, C. Licht, and P. Muus Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome N Engl J Med 368 23 2013 2169 2181
2. M. Noris, M. Galbusera, and S. Gastoldi Dynamics of complement activation in aHUS and how to monitor eculizumab therapy Blood 124 11 2014 1715 1726
3. Volokhina EB, Westra D, van der Velden TJ, van de Kar NC, Mollnes TE, van den Heuvel LP. Complement activation patterns in atypical hemolytic uremic syndrome during acute phase and in remission [published online ahead of print July 31, 2014]. Clin Exp Immunol. http://dx.doi.org/10.1111/cei.12426.
4. S.R. Cataland, V.M. Holers, S. Geyer, S. Yang, and H.M. Wu Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP Blood 123 24 2014 3733 3738